OLMASTRONI, ELENA
OLMASTRONI, ELENA
Dipartimento di Scienze Farmacologiche e Biomolecolari Rodolfo Paoletti
ARE WE UNDERESTIMATING THE BENEFITS OF LIPID-LOWERING THERAPIES?
2026 A. Pirillo, M. Casula, E. Olmastroni, S. Scotti, A. Corsini, A.L. Catapano
CX3CR1-T280M polymorphism and end-stage renal disease development in chronic kidney disease.
2026 M. Gatti, I. Baragetti, A. Baragetti, L. Buzzi, A. Lupi, A. Fassio, E. Olmastroni, A. Catapano, P. Fabbrini
Effect of angiopoietin-like protein 3 inhibitors on lipid profile and other biomarkers: a meta-analysis of randomized controlled trials
2026 S. Xie, F. Galimberti, E. Olmastroni, A.L. Catapano, M. Casula
Real-world management of familial hypercholesterolemia in paediatric patients: a 3-year follow-up from the LIPIGEN registry
2026 F. Galimberti, M.E. Capra, E. Olmastroni, D. Braghiroli, G. Banderali, F. Baratta, G. Biasucci, M. Biolo, P.S. Buonuomo, A.B. Cefalù, F. Cipollone, N. Citroni, S. D'Addato, S. Genovesi, O. Guardamagna, L. Iughetti, G. Mandraffino, I. Minicocci, G.G. Mombelli, T. Montalcini, F. Nascimbeni, A. Passaro, M. Pirro, E. Rinaldi, F. Sbrana, R. Scicali, P. Suppressa, P.J. Werba, M.G. Zenti, M. Arca, M. Averna, P. Tarugi, S. Calandra, A.L. Catapano, C. Pederiva, M. Casula, F. Abello, V. Bianconi, M. Brambilla, P. Bruzzi, A. Cicero, N. Cocomello, D. D'Ardes, L. D'Erasmo, B.D. Pino, G. Fainelli, Y. Ferro, E. Formisano, R. Franceschi, A. Giammanco, M. Giussani, S. Lugari, M. Lutterotti, S. Moriglia, S. Muntoni, C. Pavanello, C. Piras, S. Piro, L. Pisciotta, L. Rizzi, E. Sani, F. Spannella, A. Toscano, D. Vecchio, A. Zambon
Colchicine and cardiovascular events: An updated meta-analysis of published randomized controlled trials
2025 S. Xie, F. Galimberti, E. Olmastroni, A.L. Catapano, M. Casula
Contribution and interaction of polygenic predisposition and family history of coronary heart disease in predicting cardiovascular risk
2025 F. Galimberti, E. Olmastroni, M. Casula, S. Xie, A.L. Catapano
Predictors and benefits of lipid-lowering therapy initiation after an atherosclerotic cardiovascular event: a retrospective cohort study
2025 M. Casula, S. Scotti, F. Galimberti, G. Matteo Bruno, G. Lorenzo Colombo, A. Alieva, S. Xie, A.L. Catapano, E. Olmastroni
Lipoprotein(a) and prothrombotic effects: Evidence from a genetic association study
2025 E. Olmastroni, J.L. Katzmann, F. Galimberti, U. Laufs, A.L. Catapano
Operational Definitions of Polypharmacy and Their Association with All-Cause Hospitalization Risk: A Conceptual Framework Using Administrative Databases
2025 S. Scotti, L. Scotti, F. Galimberti, S. Xie, M. Casula, E. Olmastroni
Enhancing Medication Adherence in Older Adults: A Systematic Review of Evidence‐Based Strategies
2025 S. Scotti, L. Pasina, C. Lunghi, E. Raschi, A. Rossi, E. Olmastroni, M. Salluzzo, S. Mucherino, V. Orlando, A. Nobili, E. Menditto, E. Poluzzi, M. Casula
Attitudes and confidence toward deprescribing: a survey among Italian general practitioners
2025 A. Rossi, S. Scotti, L. Perrella, F. Galimberti, E. Olmastroni, E. Menditto, V. Orlando, I. Ardoino, C. Franchi, M. Casula
Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials
2024 S. Xie, F. Galimberti, E. Olmastroni, T.F. Luscher, S. Carugo, A.L. Catapano, M. Casula, C. Wanner, S. Yusuf, A. Maggioni, A. Kirby, H. Ogawa, E.K. Hoogeveen, I. Seljeflot, K. Welty, M. Benderly, J.E. Manson, K. Wolski, C.P. Cannon, F.J. Raal, D. Kallend, J. Foody, M. Louie
A newly developed method for assessing co-exposure to free dose combinations: a proof-of-concept study using antihypertensive medications in Danish registers
2024 M. Antonietta Barbieri, S. Marie Neumann Nielsen, A. Rossi, E. Olmastroni, M. Casula, E. Spina, M. Sessa
Approaches to Deprescribing Proton Pump Inhibitors in Clinical Practice: A Systematic Review
2024 A. Rossi, L. Perrella, S. Scotti, E. Olmastroni, F. Galimberti, I. Ardoino, V. Orlando, E. Menditto, C. Franchi, M. Casula
Plasma proteins associate with carotid plaques and predict incident atherosclerotic cardiovascular events
2024 A. Baragetti, L. Grigore, E. Olmastroni, E. Mattavelli, A. Catapano
Genetic heterogeneity of familial hypercholesterolaemia in two populations from two different countries
2024 A. Alieva, A. Di Costanzo, M. Gazzotti, O. Reutova, E. Usova, V. Bakaleiko, M. Arca, L. D'Erasmo, F. Pellegatta, F. Galimberti, E. Olmastroni, A. Catapano, M. Casula
Effect on C‐reactive protein levels of the addition of ezetimibe, bempedoic acid, or colchicine to statin treatment: A network meta‐analysis
2024 S. Xie, F. Galimberti, E. Olmastroni, A.L. Catapano, M. Casula
Longevity-associated BPIFB4 gene counteracts the inflammatory signaling.
2024 M. Cattaneo, A. Baragetti, A. Malovini, E. Ciaglia, V. Lopardo, E. Olmastroni, M. Casula, C. Ciacci, A. Catapano, A. Puca
Ezetimibe: Integrating Established Use with New Evidence - A Comprehensive Review
2024 E. Olmastroni, S. Scotti, F. Galimberti, S. Xie, M. Casula
Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study
2023 M. Casula, M. Gazzotti, M.E. Capra, E. Olmastroni, F. Galimberti, A.L. Catapano, C. Pederiva